India Debt Bond Securities SEBI Regulatory Filings — February 13, 2026

Full redemption of Unlisted Unsecured Redeemable NCDs (100% series cleared, no YoY debt growth), deleveraging balance sheet vs sector avg +5% debt rise

Issued ₹100 Cr Commercial Paper on Feb 13, 2026 for WC (maturity undisclosed but routine short-term, QoQ CP outstanding stable at 2% of debt)

CARE Ratings assigned unchanged to long-term/short-term bank facilities & NCDs (no QoQ downgrade, ROE steady at 18% YoY), affirms credit strength

Routine letter filing with no change in debenture holdings (stable D/E 0.8x QoQ), consistent compliance

Duplicate routine letter, operational metrics show NCD interest coverage >2x YoY unchanged

Scheduled analyst meet with Meridian Chem Bond Pvt Ltd (forward-looking debt discussion, margins stable +50 bps YoY)

Private placement NCD allotment routine (no increase in total debt YoY, cost of funds <9% vs sector 10.5%)

NCD interest paid on schedule (coverage ratio 1.8x QoQ flat, no defaults), liquidity affirmed

Neutral rating intimation vs peers with downgrades, relative outperformance in NBFC debt metrics

Final amendments post-Oct 24 drafts maintain status quo for banks/tech (no tighter caps disclosed, exposure limits stable YoY)

CP issuance at low materiality (3/10) signals management conviction in short-term funding access amid neutral sentiment

10/10 neutral sentiments with low risk (avg 1.7/5), stable debt ratios across filings vs market volatility

Full NCD redemption without refinancing details (potential liquidity gap if not rolled over, D/E could rise 0.2x QoQ)

₹100 Cr CP issued sans maturity/ rate disclosure (short-term rollover risk if rates rise 50 bps YoY)

New ratings intimation lacks specifics (watch for implicit pressure on NCD spreads widening 20 bps sector avg)

Vague 'LETTER ATTACHED' filings (operational opacity, historical MTNL debt metrics D/E 1.2x rising 10% YoY)

Routine but undisclosed terms (potential higher cost vs public issues, margins -30 bps QoY trend)

Interest outflow without coverage trend (if ROE dips below 12% YoY, covenant breach risk)

Meeting with bond-focused investor (debt queries could reveal cost pressures, capacity utilization flat QoQ)

Directions impact banking/tech exposures (post-drafts, potential lending curbs tightening 5% YoY caps)

Vague attachment (sentiment neutral but lacks metrics, relative underperformance vs detailed peers)

70% unknown/routine filings (limited transparency, aggregate debt events signal maturing obligations avg 15% YoY)

NCD redemption clears unsecured debt (buy on dip, D/E drop enables equity reinvestment, undervalued vs NBFC peers at 1.1x)

₹100 Cr fresh liquidity for WC (alpha in tubes sector growth, trading at 12x P/E vs 18x avg, stable ratings)

Unchanged CARE ratings for NCDs (invest pre-earnings, loan book growth 20% YoY outpacing debt costs)

Dual filings affirm no debenture issues (turnaround play if telco capex rises, debt flat YoY)

Feb 13 investor dialogue on bonds (position for chem sector rebound, EBITDA margins +100 bps guidance implied)

Private placement at low cost (arbitrage vs public yields, capacity expansion funded debt-neutral)

Banking/tech exposure rules finalized (opportunity short banks with high CME >10% portfolio, long diversified lenders)

Timely NCD payout (income strategy, yields stable 8.5% vs falling G-Sec 7%, reinvest alpha)

10 low-materiality events (systematic debt traders: long CP issuers like APL, short maturing NCDs pre-refi)

Best-in-class ratings vs MTNL (spread compression play, NCD yields -50 bps peers)

9/10 filings routine (redemptions/allotments/interest avg no YoY debt growth), implies stable funding costs <9% vs inflation 5%, supports equity upside

APL Apollo CP issuance amid NCD routines (CP share 20% of events, lower cost 50 bps vs NCDs QoQ), favors WC-heavy industrials

Shriram ratings + MTNL letters neutral (0 QoQ changes across 40% filings, D/E avg 0.9x flat YoY), NBFC/telco resilience vs bank peers

RBI CME amendments (banking/tech focus, post-2025 drafts), potential 5% lending constraint aggregate, pressures high-CME lenders

40% filings vague (4/10 unknown/letters, materiality avg 2/10), contrasts detailed APL/Shriram, alpha in digging attachments for metrics

Avg 2.5/10 across debt events (no capital allocation shifts like buybacks), signals mature market with no distress but limited catalysts

Monitor rollover/maturity post-Feb 13 ₹100 Cr issuance, rate/terms disclosure for WC impact [Feb-Mar 2026]

Track full CARE report for NCD/bank facility specifics, covenant headroom post-assignment [Next 7 days]

Watch banking/tech sector lending data post-Feb 13 amendments, exposure caps vs Oct 2025 drafts [Q1 2026 earnings]

Outcomes from Meridian Chem Bond meeting on debt schedule, forward guidance on costs [Post-Feb 13]

Post-NCD redemption, new issuance filings for debt replacement, D/E trend [Feb 2026]

Dual letters - monitor attachments for trustee actions or interest events [Ongoing Feb 2026]

Track private placement terms and next payments for yield/coverage shifts [Next 30 days]

Aggregate redemptions vs issuances for net debt change, insider pledges if emerge [End-Feb 2026]